Company news
Apollomics Inc. (NASDAQ:APLM) news
Apollomics Inc. news releases on 6ix. Latest, Aug 11, 2026: Apollomics Announces $10 Million Private Placement Transaction
Press releases & updates
Apollomics Announces $10 Million Private Placement Transaction
August 11, 2026
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
July 13, 2026
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
June 23, 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
April 26, 2026
Apollomics Inc. Announces $2.0 Million Bridge Financing
March 31, 2026
Apollomics Reports First Half 2025 Financial Results
December 22, 2025
Apollomics Announces Settlement of Cayman Litigation
November 19, 2025
Apollomics Announces Changes to its Board of Directors and Composition of Committees
November 16, 2025
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
October 15, 2025
Apollomics, Inc. Company Operational Continuity Update
October 12, 2025
Apollomics : Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain
September 23, 2025
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
April 3, 2025
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
March 31, 2025
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
December 19, 2024
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
December 11, 2024
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
December 9, 2024
Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
November 22, 2024
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
November 20, 2024
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
September 15, 2024
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
August 13, 2024
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
August 12, 2024
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
July 15, 2024
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
July 2, 2024
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2024
Apollomics Announces Presentation at the 2024 BIO International Convention
May 28, 2024
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 7, 2024
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 24, 2024
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 9, 2024
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 1, 2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 27, 2024
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 25, 2024
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 3, 2024
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 2, 2024
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 3, 2023
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 27, 2023
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 15, 2023
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 30, 2023
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 25, 2023
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 22, 2023
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 15, 2023
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 27, 2023